Glenmark Pharma expecting 12 to 14% growth in its India revenues during FY20

03 May 2019 Evaluate

Glenmark Pharmaceuticals is expecting 12 to 14% growth in its India revenues during the current fiscal (FY20). The company had reported Rs 2514 crore revenues from India in FY18 against Rs 2303 crore in the previous year at growth of 10%. During the first nine months of the FY19, the company reported Rs 2109 crore revenues.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2006.90 -71.40 (-3.44%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×